PG Stock Analysis: Procter & Gamble | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 343.259m USD | 12M Return: -4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.19B
EPS Trend: 91.6%
Qual. Beats: 0
Rev. Trend: 87.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Procter & Gamble (NYSE: PG) is a global consumer packaged goods company headquartered in Cincinnati, Ohio, and founded in 1837. It operates through five reporting segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The company sells a broad portfolio of household-name brands, including Pampers and Luvs (diapers and wipes), Tide, Ariel, Downy, and Gain (laundry), Gillette and Venus (grooming), Crest and Oral-B (oral care), Olay and SK-II (skin care), and Bounty, Charmin, and Puffs (paper products).
P&G distributes its products through a wide range of channels, including mass merchandisers, grocery and drug stores, specialty beauty retailers, membership clubs, e-commerce platforms, airport duty-free outlets, and professional channels. Because the company sits in the Consumer Staples sector, its revenue is anchored in everyday essentials such as hygiene, cleaning, and personal care, which generally support steady, recurring demand through economic cycles. P&Gs business model is built on global brand equity, large-scale manufacturing, and deep relationships with major retailers, giving it broad shelf presence in nearly every country where consumer packaged goods are sold.
- Fabric and home care volumes recover after pricing-driven softness
- Beauty organic sales outpace company average on SK-II and Olay strength
- Sustained dividend hikes and buybacks anchor total shareholder return thesis
| Net Income: 16.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: -14.35% < 20% (prev -12.65%; Δ -1.69% < -1%) |
| CFO/TA 0.16 > 3% & CFO 20.3b > Net Income 16.0b |
| Net Debt (25.2b) to EBITDA (24.4b): 1.03 < 3 |
| Current Ratio: 0.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.42b) vs 12m ago -1.30% < -2% |
| Gross Margin: 50.18% > 18% (prev 51.16%; Δ -0.98% > 0.5%) |
| Asset Turnover: 69.14% > 50% (prev 67.30%; Δ 1.84% > 0%) |
| Interest Coverage Ratio: 24.23 > 6 (EBIT TTM 21.3b / Interest Expense TTM 877.0m) |
| A: -0.10 (Total Current Assets 26.2b - Total Current Liabilities 38.7b) / Total Assets 127b |
| B: 1.03 (Retained Earnings 130b / Total Assets 127b) |
| C: 0.17 (EBIT TTM 21.3b / Avg Total Assets 126b) |
| D: 0.75 (Book Value of Equity 54.3b / Total Liabilities 72.2b) |
| Altman-Z'' = 4.63 = AA |
| DSRI: 0.95 (Receivables 6.06b/6.18b, Revenue 87.0b/84.3b) |
| GMI: 1.02 (GM 51.16% / 50.18%) |
| AQI: 0.98 (AQ_t 0.59 / AQ_t-1 0.61) |
| SGI: 1.03 (Revenue 87.0b / 84.3b) |
| TATA: -0.03 (NI 16.0b - CFO 20.3b) / TA 127b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 30, 2026, the stock is trading at USD 146.10 with a total of 12,663,401 shares traded. Over the past week, the price has changed by -1.30%, over one month by -0.85%, over three months by +0.50% and over the past year by -3.97%.
Current recommended Stop Loss: 141.50 (which is 3.1% or 1.4 ATR below the current price).
Procter & Gamble has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy PG.
- StrongBuy: 9
- Buy: 5
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 163.6 | 12% |
P/E Trailing = 21.7343
P/E Forward = 20.8768
P/S = 4.1654
P/B = 6.4395
P/EG = 4.175
Revenue TTM = 87.0b USD
EBIT TTM = 21.3b USD
EBITDA TTM = 24.4b USD
Long Term Debt = 25.0b USD (from longTermDebt, last fiscal year)
Short Term Debt = 11.3b USD (from shortTermDebt, last quarter)
Debt = 35.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 956.0m
Net Debt = 25.2b USD (calculated: Debt 35.1b - CCE 9.94b)
Enterprise Value = 368b USD (343b + Debt 35.1b - CCE 9.94b)
Interest Coverage Ratio = 24.23 (Ebit TTM 21.3b / Interest Expense TTM 877.0m)
EV/FCF = 23.15x (Enterprise Value 368b / FCF TTM 15.9b)
FCF Yield = 4.32% (FCF TTM 15.9b / Enterprise Value 368b)
FCF Margin = 18.28% (FCF TTM 15.9b / Revenue TTM 87.0b)
Net Margin = 18.44% (Net Income TTM 16.0b / Revenue TTM 87.0b)
Gross Margin = 50.18% ((Revenue TTM 87.0b - Cost of Revenue TTM 43.4b) / Revenue TTM)
Gross Margin QoQ = 48.50% (prev 49.51%)
Tobins Q-Ratio = 2.91 (Enterprise Value 368b / Total Assets 127b)
Interest Expense / Debt = 2.50% (Interest Expense 877.0m / Debt 35.1b)
Taxrate = 20.77% (4.23b / 20.4b)
NOPAT = 16.8b (EBIT 21.3b * (1 - 20.77%))
Current Ratio = 0.68 (Total Current Assets 26.2b / Total Current Liabilities 38.7b)
Debt / Equity = 0.65 (Debt 35.1b / totalStockholderEquity, last quarter 54.3b)
Debt / EBITDA = 1.03 (Net Debt 25.2b / EBITDA 24.4b)
Debt / FCF = 1.58 (Net Debt 25.2b / FCF TTM 15.9b)
Total Stockholder Equity = 53.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.75% (Net Income 16.0b / Total Assets 127b)
RoE = 29.84% (Net Income TTM 16.0b / Total Stockholder Equity 53.8b)
RoCE = 26.98% (EBIT 21.3b / Capital Employed (Equity 53.8b + L.T.Debt 25.0b))
RoIC = 17.77% (NOPAT 16.8b / Invested Capital 94.8b)
WACC = 4.96% (E(343b)/V(378b) * Re(5.27%) + D(35.1b)/V(378b) * Rd(2.50%) * (1-Tc(0.21)))
Discount Rate = 5.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.52 | Cagr: -0.89%
[DCF] Terminal Value 77.71% ; FCFF base≈15.2b ; Y1≈17.1b ; Y5≈24.3b
[DCF] Fair Price = 146.8 (EV 367b - Net Debt 25.2b = Equity 342b / Shares 2.33b; r=8.35% [WACC [floored]]; 5y FCF grow 13.31% → 2.50% )
EPS Correlation: 91.61 | EPS CAGR: 5.13% | SUE: 0.82 | # QB: 0
Revenue Correlation: 87.03 | Revenue CAGR: 1.32% | SUE: -0.18 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.92 | Chg30d=-2.59% | Revisions=-50% | Analysts=13
EPS current Year (2026-06-30): EPS=6.88 | Chg30d=-0.20% | Revisions=-40% | GrowthEPS=+0.8% | GrowthRev=+3.3%
EPS next Year (2027-06-30): EPS=7.05 | Chg30d=-0.47% | Revisions=-44% | GrowthEPS=+2.5% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: -64% (up=1, down=10)